AI Article Synopsis
- The study examines the role of tumor-infiltrating lymphocytes (TILs) and mismatch repair (MMR) status as potential biomarkers for immunotherapy in advanced noncolorectal gastrointestinal cancers.
- A retrospective analysis of 146 patients showed that while most had proficient MMR status, a higher number of TILs (>5) correlated with improved survival rates, particularly in patients with hepatocellular carcinoma.
- The findings indicate that MMR-deficient tumors are rare in this patient population and suggest that assessing TIL levels could help determine eligibility for immunotherapy treatments.
Article Abstract
Background: Tumor-infiltrating lymphocytes (TILs) and mismatch repair gene mutation (MMR) status are emerging biomarkers in immunotherapy. MMR status and TILs have significant clinical implications with regard to treatment with checkpoint inhibitors. We designed a study to determine the frequency and prognostic utility of TILs and MMR in advanced unresectable noncolorectal gastrointestinal (NCGI) malignancies.
Methods: This is a retrospective cohort study of patients who were diagnosed with advanced noncolorectal gastrointestinal tumors. Biopsy specimens were tested for MMR status by immunohistochemistry along with evaluation of TILs. Kaplan-Meier analysis was performed to determine the impact of TILS and MMR on survival.
Results: We analyzed 146 patients; the mean age at diagnosis was 66.4 ± 11.2 years. 65.8% patients were male, and 62.3% patients had stage 4 disease. All cases had proficient MMR status. The percentage of patients with TILs >5 was 50.7%. There was no statistically significant difference in median overall survival (OS) by TILs when stratified by stage of tumor. When stratified by type of tumor, median OS by TILs level was significantly different for hepatocellular cancers (⩽5 TILs, 86 days versus >5 TILs 312 days, P = .031).
Conclusions: Our study suggests that MMR-deficient tumors are quite rare in advanced NCGI malignancies. More than 5 TILs per high power field, evaluated simply on a routine hematoxylin and eosin-stained glass slide confer a better prognosis to most noncolorectal gastrointestinal malignancies, especially hepatocellular carcinoma. This has immense clinical utility with regard to eligibility for immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1066896918809460 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.
Signal Transduct Target Ther
December 2024
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- * In Cohort A (colorectal cancer), the objective response rate (ORR) was 40.4% with a median progression-free survival (PFS) of 8.7 months, while in Cohort C (non-colorectal/non-esophageal GI cancer), the ORR was 31.8% with a PFS of 5.8 months.
- * The study indicated promising antitumor activity, enabling liver metastasectomy in some patients, without introducing new safety issues.
Is There a Role for Locoregional Therapies for Non-colorectal Gastrointestinal Malignancies?
Hematol Oncol Clin North Am
February 2025
Digestive Surgery Division, Liver Surgery Unit, Department of Gastroenterology, University of Sao Paulo Medical School, Avenida Doutor Enéas de Carvalho Aguiar, 255, Instituto Central, 9° andar, Sala 9074, Cerqueira Cesar, São Paulo, São Paulo CEP: 05403-900, Brazil. Electronic address:
The liver is the most common site of metastases from solid gastrointestinal tract tumors. Over the past few decades, the role of locoregional therapies, resection and thermal ablation, for neuroendocrine and colorectal liver metastases has been widely studied. However, for liver metastases originating from other gastrointestinal organs, the role of locoregional treatment remains unclear.
View Article and Find Full Text PDFClinicopathologic Features of Gastrointestinal Tract Langerhans Cell Histiocytosis.
Mod Pathol
September 2024
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Pathology, Now with Case Western Reserve University, Cleveland, Ohio. Electronic address:
Gastrointestinal (GI) tract involvement by Langerhans cell histiocytosis (LCH) is rare and its clinicopathologic characteristics have only been described in case reports and small series. We reviewed hematoxylin and eosin and CD1a, S100, and Langerin immunohistochemical-stained slides from 47 patients with well-documented demographic and clinical findings. Our cases included 8 children and 39 adults, with a mean follow-up of 63 months.
View Article and Find Full Text PDFFrequency of Common and Uncommon Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies.
Cancers (Basel)
May 2024
Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Background: The predictive and prognostic role of alterations has been evaluated in colorectal cancer (CRC); however, alterations have not been fully characterized in non-CRC gastrointestinal (GI) malignancies. In the present study, we report the frequency and spectrum of alterations among patients with non-CRC GI malignancies.
Methods: Patients with CRC and non-CRC GI malignancies who underwent somatic tumor profiling via a tissue-based or liquid-based assay were included in this study.
Sporadic deficient mismatch repair in colorectal cancer increases the risk for non-colorectal malignancy: A European multicenter cohort study.
J Surg Oncol
June 2024
Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden.
Background And Objectives: Disparities between tumors arising via different sporadic carcinogenetic pathways have not been studied systematically. This retrospective multicenter cohort study evaluated the differences in the risk for non-colorectal malignancy between sporadic colorectal cancer (CRC) patients from different DNA mismatch repair status.
Methods: A retrospective European multicenter cohort study including in total of 1706 CRC patients treated between 1996 and 2019 in three different countries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!